The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
Darren Richard Feldman
No relevant relationships to disclose
James Hu
No relevant relationships to disclose
Tanya B. Dorff
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Lindsay Joy Van Alstine
No relevant relationships to disclose
Lamia Momen
No relevant relationships to disclose
Maryann Carousso
No relevant relationships to disclose
Amanda Hughes
No relevant relationships to disclose
Jolie Snively-Solomon
No relevant relationships to disclose
Charlean Ketchens
No relevant relationships to disclose
Joel Sheinfeld
No relevant relationships to disclose
Manjit S. Bains
No relevant relationships to disclose
Dean F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb
George J. Bosl
No relevant relationships to disclose
Robert John Motzer
Research Funding - Bristol-Myers Squibb
David I. Quinn
No relevant relationships to disclose